Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — JP Morgan Healthcare Conference 2017
25 slides from Elekta Ab Class B's conference presentation, Jan 11, 2017
Slide 1: Elekta – JP Morgan Healthcare Conference 2017
Elekta – JP Morgan Healthcare Conference 2017 Richard Hausmann President and CEO
Slide 2: Important information
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forward-looking statements are based on current expectations about future event
Slide 3: Richard Hausmann background
Background Over 30 years experience in medical device industry – Physicist by education Siemens • Magnetic Resonance & Computed Tomography • President and CEO of Computed Technology • President and CEO of Siemens China GE Healthcare • President and CEO Global MR Business • Turnaround USD 2.4 bn busi
Slide 4: Elekta – global leader in radiation therapy equipment and oncology informatics
Elekta – global leader in radiation therapy equipment and oncology informatics • One of the two major global companies in radiation therapy • Active on 120 markets globally • Market leader in Asia Pacific and Europe • Over 1 M treatments per year with our 3,650 installed systems • Around 3,600 emplo
Slide 5: Radiation therapy – underlying growth potential for foreseeable future
Radiation therapy– underlying growth potential for foreseeable future Lack of capacity At least 10,000 additional linacs are required to meet current needs* Underlying growing need Innovation enable • New cancer cases to grow from 15 M per year (today) to broader usage Additional cancer types 24 M (
Slide 6: Oncology Informatics Portfolio
EMR PARTICAL RADIATION ONCOLOGY & MEDICAL THERAPY ONCOLOGY INFORMATICS Treatment pathway centric REGISTRY Vendor & therapy agnostic Localized to markets SERVICES & SUPPORT MOSAIQ MOSAIQ MOSAIQ METRIC/LGK Oncology specific EMR Oncology Analytics Image & Plan Review Cancer Registries SURGERY Oncology
Slide 7: Elekta's revenue base (rolling 12 months)
Elekta’s revenue base (rolling 12 months) Oncology Informatics Oncology informatics Linear 16% Accelerators* Linear 16% Brachy- accelerators* Brachy therepy* 62% 9% 9% Therapy* 62% 13% Neuroscience* 13% Neuroscience* 7 | Focus where it matters *Including treatment planning software and service
Slide 8: Elekta's market position in linear accelerators
Elekta’s market position in linear accelerators NEW ORDERS* NEW SOCKETS** INSTALLED BASE Other Other 10% Other 14% 23% Elekta Elekta 39% Elekta 24% 51% Varian Varian Varian 51% 35% 53% *Order intake of linear accelerators in FY 2015/16 **New radiation therapy departments or expansion by new bunker 8
Slide 9: Focus areas: 1. Innovation 2. Transformation
Focus areas: 1. Innovation 2. Transformation 9
Slide 10: Focus areas: 1. Innovation 2. Transformation
Focus areas: 1. Innovation 2. Transformation To create the possible we have to constantly try the impossible. Hermann Hesse 10
Slide 11: The innovation opportunities for Radiotherapy
The innovation opportunities for Radiotherapy More outcome and focus where it matters Image guidance Workflow Automation • High field MR as the • Integrated and • Big data applications ultimate soft tissue automated workflows • Decision support with imaging tool on treatment units self learning • Ad
Slide 12: Wrapping high dose tight to a target is sufficient in static situations
Wrapping high dose as tight as possible to a target is sufficient in static situations… 12 | Focus where it matters
Slide 13: Targets often move and only advanced imaging helps reduce margins
…but targets often move and only advanced imaging helps reduce margins and further limit dose to healthy tissue… 13 | Focus where it matters
Slide 14: Day-to-day changes require seamless online plan adaptation
…and for day-to-day changes of shape and position, seamless and on-line plan adaptation is vital. ONLINE ADAPTIVE • Diagnostic Imaging • Dose Calculation • Dose Adjustment • Repositioning • Plan Adaptation
Slide 15: MR-Linac
MR-Linac Cone Beam IGRT (New) (Today) Esophagus MR-Linac Bladder Brings together the capability of high-field diagnostic MR imaging, the highest standard of precision radiation therapy delivery and sophisticated adaptive workflow software. …for the first time! Rectal tumor
Slide 16: A new paradigm
A new paradigm Conventional IGRT workflow Locating Treat Imaging & Locating target Treat Planning Locating target Treat Simulation Locating target Treat target Plan = dose objectives Adjust patient position to the plan Adaptive workflow Adapt plan & deliver Imaging & Initial Adapt plan & deliver Sim
Slide 17: How to navigate in today's RT world
How to NAVIGATE in todays RT world Plan dose Adaptive Navigation provides actual information to decide how to best reach destination Anatomical changes IGRT added navigation Patient moves Faster cars Arrive at actual delivered dose 17 | Focus where it matters 17
Slide 18: MR-Linac progress – first commercial orders signed
MR-Linac progress – first commercial orders signed* Odense University Hospital Launch in Ambition: second half of 75 orders calendar year until 2019 +7 reserach consortium members 2017 *All in line with local regulatory requirements
Slide 19: Focus areas: 1. Innovation 2. Transformation
Focus areas: 1. Innovation 2. Transformation 19
Slide 20: Transformation for profitable growth on track
Kan vi göra denna Transformation for snyggare? profitable growth on track Objectives • Improve processes and structure • Reduce cost and restore profitability • Strengthen cash flow and reduce working capital • Improve customer experience and drive excellence in product development
Slide 21: On track to reach EBITA margin of >20%
On track to reach EBITA margin of >20% Margin development* Transformation program targets 47% 46% 43% EBITA margin of 20% by 2017/18 40% 41% 41% Cost reductions of 23% 22% 20% Net working capital Implemented 14% 15% 16% SEK 700**M to sales below produce-to-order process. One-off with full effect 5%
Slide 22: Net working capital to sales ratio has improved
Net working capital to sales ratio has improved Net working captial / net sales* Further initiatives 10% • Inventory reduction plan of SEK >200 M Target: 5% • Accrued income reduction 5% – focus on project 4% acceptances 0% Q1 Q2 Q3 Q4 Q1 Q2 2015/16 2015/16 2015/16 2015/16 2016/17 2016/17 22 | Focus
Slide 23: Priorities, organizational structure and tools in place
Priorities, organizational structure and tools in place Values Organization Priorities We work as one team We do what we say We keep thinking forward - Company organized in Updated brand line with three key Growth processes Cost 23 | Focus where it matters
Slide 24: Unique position, strong product offering, transformation on track
UNIQUE POSITION in long-term growing market STRONG PRODUCT OFFERING and leading R&D portfolio TRANSFORMATION ON TRACK for operational excellence and profitable growth
Slide 25: Focus where it matters.
Focus where it matters. CyElekta